Dr. Dominik Lock
R&D Group Leader – Early Drug Development, Miltenyi Biotec
Dr. Dominik Lock is leading the research group Early Drug Development at Miltenyi Biotec. His work evolves around non-viral gene engineering, process development as well as early pre-clinical development. His team solves challenges related to adoptive T cell therapies by inventing innovative technologies and novel manufacturing processes. By improving the potential of gene-engineered T cells, Dominik Lock strongly contributes to the company’s vision to ‘make cancer history’.
Advertisement
